2022
DOI: 10.1186/s12866-022-02662-3
|View full text |Cite
|
Sign up to set email alerts
|

Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates

Abstract: Background Proteus mirabilis is an opportunistic pathogen, causing a variety of community-acquired and nosocomial illnesses. It poses a potential threat to patients via the production of β-lactamases, which decrease the efficacy of antimicrobial treatment and impair the management of its pathogenicity. Hence, this study was established to determine the prevalence of extended-spectrum β-lactamases (ESBLs), AmpC, and carbapenemases of P. mirabilis isolated from various clinical specimens. … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

2
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 60 publications
2
2
0
Order By: Relevance
“…Among our isolates, bla CTX‐M , bla TEM and bla CTX‐M‐2 were the most commonly detected ESBL genotypes. This agrees with other studies conducted in Korea, Italy and Brazil that reported the presence of genes from P. mirabilis (Ahn et al., 2017 ; Luzzaro et al., 2001 ; Sanches et al., 2023 ) but differs with the study conducted in Egypt (Shaaban et al., 2022 ), where the bla SHV , bla ampC and bla VIM‐1 were the most detected genes. Multiple ESBL resistance genes may impart resistance to β‐lactamases regardless of reduced expression of one or more of those genes (Gundran et al., 2019 ).…”
Section: Discussionsupporting
confidence: 89%
“…Among our isolates, bla CTX‐M , bla TEM and bla CTX‐M‐2 were the most commonly detected ESBL genotypes. This agrees with other studies conducted in Korea, Italy and Brazil that reported the presence of genes from P. mirabilis (Ahn et al., 2017 ; Luzzaro et al., 2001 ; Sanches et al., 2023 ) but differs with the study conducted in Egypt (Shaaban et al., 2022 ), where the bla SHV , bla ampC and bla VIM‐1 were the most detected genes. Multiple ESBL resistance genes may impart resistance to β‐lactamases regardless of reduced expression of one or more of those genes (Gundran et al., 2019 ).…”
Section: Discussionsupporting
confidence: 89%
“…Our findings are fairly parallel to the results from a previous Nigerian study, where 21% of the investigated Proteeae were confirmed phenotypically to be ESBL producers [19]. Amongst our P. mirabilis isolates, the rate of ESBL production is considerably lower than that from a recent report from Egypt [20]. On the other side, 21.6% of the recovered Providencia species isolates (n=8) produced ESBLs, compared to 52% from an Italian university hospital [21].…”
Section: Discussionsupporting
confidence: 87%
“…Almost half of the MDR P. mirabilis isolates (50.8%; 30/59) were obtained from urine samples. This result specifies that P. mirabilis has a greater predisposition for colonizing the urinary tract and exerting resistance to various antibiotics [20]. A recent single-centered, observational, retrospective study from Saudi Arabia reported a lower rate of MDR amongst Proteus species (12.5%).…”
Section: Discussionmentioning
confidence: 93%
“…A research article report and a review [ 168 , 172 ] have shown that the blasshv- mediated phenotypic and genotypic resistance could be so complex to explain at times due to various factors. Summarily the factors as pointed out in literature are: 1. the balshv family is highly diverse and complex [a large number of allelic variants including extended-spectrum β-lactamases [ESBL], non-ESBL and several not classified variants exist] in nature, 2. β-lactamase produced in small quantity do not contribute significantly to antibiotic resistance and, 3. overproduction of a β-lactamases could mask the effect of other β-lactamases [ 168 , 173 178 ]. Furthermore, Vibrio parahaemolyticus isolates that are more susceptible to a third-generation cephalosporin [ceftazidime] than fourth-generation cephalosporin [cefepime] have been reported [ 179 ].…”
Section: Discussionmentioning
confidence: 99%